View More Recent Stories
-
BMO Capital Upgrades Abbvie (ABBV) to Outperform
-
Positive Read-Through for Gilead Sciences (GILD) from ABBV/PCYC Deal
-
AbbVie's (ABBV) Pharmacyclics (PCYC) Deal Expensive, Done Out of Weakness - BMO Capital
-
Notable Analyst Rating Changes 2/9: (MOS) (PFE) (AMC) Upgraded; (CENX) (ANF) (RF) Downgraded
-
Abbvie (ABBV) PT Cut to $60 at BMO Capital as Cautious Thesis Materializing Faster
-
Streetinsider.com's Hot Lunchtime Reads 12/22: (GILD) (CUBA) (VHC) (ACHN)
-
Buy Gilead Sciences (GILD) on Weakness, BMO Capital Says; PT Dropped $20 on News
-
AbbVie's (ABBV) VIEKIRA PAK Seen as Limited Threat to Gilead's (GILD) HCV Dominance, BMO Capital Says
-
Notable Analyst Rating Changes 11/14: (RTN) (ESRT) (GERN) Upgraded; ((TJX) (LULU) (WMT) Downgraded
-
Notable Analyst Rating Changes 11/7: (CA) (GNC) (SPLK) Upgraded; (OXY) (ABBV) (SLXP) Downgraded
-
UPDATE: BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
Notable Analyst Rating Changes 05/07: (JCP) (ABBY) (FE) Upgraded; (WFM) (GNC) (GRPN) Downgraded
-
Notable Analyst Rating Changes 12-19: (ELY) (FRX) (OMC) Upgraded; (SMTC) (F) (ABBV) Downgraded
-
Notable Analyst Rating Changes 12/03: (ABBV) (AAPL) (FRX) Upgraded; (PFE) (DIS) (AT) Downgraded
-
BMO Capital Upgrades Abbvie (ABBV) to Outperform
-
BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
Notable Analyst Rating Changes 01/02: (WAG) (X) (MAR) Upgraded; (SKUL) (LNKD) (KSS) Downgraded
-
BMO Capital Starts Abbvie (ABBV) at Outperform

